Increasing Neisseria gonorrhoeae resistance to ceftriaxone, the last antibiotic recommended for empiric gonorrhea treatment, poses an urgent public health threat. However, the genetic basis of reduced susceptibility to ceftriaxone is not completely understood: while most ceftriaxone resistance in clinical isolates is caused by target site mutations in penA, others lack these mutations. We show that penA-independent ceftriaxone resistance has evolved multiple times through distinct mutations in rpoB and rpoD. We identify five mutations in these genes that each increase resistance to ceftriaxone, including one mutation that arose independently in two lineages, and show that clinical isolates from multiple lineages are a single nucleotide change from ceftriaxone resistance. These RNA polymerase mutations result in large-scale transcriptional changes without altering susceptibility to other antibiotics, reducing growth rate, or deranging cell morphology. These results underscore the unexpected diversity of pathways to resistance and the importance of continued surveillance for novel resistance mutations.
Sequencing data have been deposited in the NCBI SRA database under accession number PRJNA540288.
N. gonorrhoeae isolates with reduced ceftriaxone susceptibilitySRA, PRJNA540288.
- Yonatan H Grad
- Yonatan H Grad
- Suzanne Walker
- Michael A Welsh
- Daniel H F Rubin
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
- Christina L Stallings, Washington University School of Medicine, United States
© 2020, Palace et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.